ArticleJournal of transplantation2011
Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab.
Article in Journal of transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design.Frontiers in nephrology · 2023Article
- Non-immunologic allograft loss in pediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2019Review
- Rituximab is not a "magic drug" in post-transplant recurrence of nephrotic syndrome.European journal of pediatrics · 2016Article
- Update on the treatment of focal segmental glomerulosclerosis in renal transplantation.World journal of transplantation · 2016Review
- Recurrent focal segmental glomerulosclerosis after kidney transplantation.Pediatric nephrology (Berlin, Germany) · 2015Article
- Article
- Recent progress in the pathophysiology and treatment of FSGS recurrence.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2013Review
- IgM contributes to glomerular injury in FSGS.Journal of the American Society of Nephrology : JASN · 2013Article
- Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis.Pediatric nephrology (Berlin, Germany) · 2013Article
- Recurrent focal segmental glomerulosclerosis: a discrete clinical entity.International journal of nephrology · 2012Article
- Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients.Advances in chronic kidney disease · 2011Review
- The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review.Journal of transplantation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation is a complication that often leads to graft loss. There is no consensus on the optimal treatment of recurrent FSGS. Rituximab, a monoclonal antibody to CD20, may be a useful treatment of this complication. Methods. We report four pediatric cases of recurrent FSGS treated with rituximab and plasmapheresis. Results. Four children (2M/2F), age 15.3 ± 2.6, with recurrent FSGS posttransplant were identified. Four doses of rituximab were administered 171 ± 180 days posttransplant and 114 ± 169 days after the start of plasmapheresis. Three children responded with complete remission, one of whom relapsed after four months. One child had a partial response with a decrease in proteinuria that was not sustained. No adverse side effects were reported during treatment or followup (mean 22.5 months). Conclusions. Rituximab is a safe and well-tolerated ancillary treatment for recurrent FSGS in pediatric patients in conjunction with plasmapheresis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.